🟢 GRAIL is trading 5% up today after Canaccord raised its target to $150

GRAIL is trading at $133.20, up 4.97%, after Canaccord Genuity raised its target to $150 from $80 and maintained a Buy rating on September 28. - The outlook followed a webcast on Galleri and the FDA advisory committee meeting. - The September 23 FDA panel vote was favorable overall, with a 6–4 key effectiveness vote; this was not a new September 28 decision. - Rising oil and yields pressured broader markets, making the analyst action the clearest company-specific explanation.